替吉奥联合顺铂与多西他赛联合顺铂治疗晚期食管癌的临床观察  

Comparative Study Of Efficacy Of S-1 Combined with Cisplatin And Docetaxel Combined with Cisplatin in Treatment of Advanced Esophageal Cancer

作　　者：马寅达[1] 郭斌[1] 

机构地区：[1]辽宁医学院附属第一医院,辽宁锦州121001

出　　处：《辽宁医学院学报》2015年第6期28-30,I0011,共4页Journal of Liaoning Medical University (LNMU) Bimonthly

摘　　要：目的分析晚期食管癌治疗中联合替吉奥及顺铂与联合多西他赛及顺铂两种治疗方案的临床治疗效果。方法对112例于2013年10月至2014年4月期间就诊于我院的晚期食管癌患者的临床资料进行回顾性分析。以接受联合替吉奥及顺铂治疗者为替吉奥组,患者58例;以接受联合多西他赛及顺铂治疗者为多西他赛组,患者54例。分析两组接受治疗后的近期疗效、中位生存期、中位无进展生存期及治疗副作用发生率。结果两组间近期治疗总有效率、生存率、中位生存期、中位无进展生存期比较均未见统计学差异(P>0.05)。同时两组随访期间治疗副作用发生率比较未见统计学差异(P>0.05)。结论在晚期食管癌的临床治疗过程中,联合替吉奥及顺铂与联合多西他赛及顺铂两种治疗方案均有着较为理想的应用效果。Objective To analyze the efficacy of both S - 1 combined with cisplatin and docetaxel combined with cisplatin in the treatment of advanced esophageal cancer. Methods 112 cases of patients with advanced esophageal cancer admitted into our hospital from October 2013 to April 2014 were retrospectively analyzed. They were divided into two groups, S - 1 group with 58 patients who were given S - 1 and cisplatin, and docetaxel group with 54 patients who were treated with docetaxel combined with cisplatin. The short - term curative effect, median survival time, median progression - free survival time, and incidence of side effect of the two groups before and after treatment were analyzed. Results There was no statistically significant difference in total effective rate, sur- vival rate, median survival time, median progression - free survival time between the two groups （ P 〉 0. 05 ）. In the meanwhile, no statistically significant difference in incidence of side effect was found during the follow - up （ P 〉 0. 05 ）. Conclusion The two thera- pies, both S - 1 combined with cisplatin and docetaxel combined with cisplatin, prove to be ideally effective in the clinical treatment for advanced esophageal cancer.

关 键 词：替吉奥 多西他赛 顺铂 食管癌 

分 类 号：R735.1[医药卫生—肿瘤]